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Objective: To assess the long-term outcomes of laparoscopic staging surgery (LSS) in treating patients
with endometrial carcinoma.
Materials and Methods: Patients with endometrial cancer who underwent LSS between June 1995 and
June 2014 were prospectively registered. Perioperative data, complications, disease recurrence, and long-
term survival were measured.
Results: The study included 287 consecutive patients [mean age (± standard deviation), 53 ± 10.4 years;
mean body mass index, 27.3 ± 6.7 kg/m2] with a median follow-up ranging from 1 to 216 months. No
laparotomy conversion was recorded for any patient. The mean operative time was 207 ± 63.5 minutes,
and the mean blood loss was 183 ± 166.7 mL. The mean numbers of pelvic nodes and para-aortic nodes
removed were 18 ± 4.8 and 8 ± 5, respectively. More than 80% of the patients had an International
Federation of Gynecology and Obstetrics (FIGO) Stage 1 disease. The overall complication rate was 3.1%,
including two patients of bladder injuries and one with bowel injury intraoperatively, and post-
operatively one patient with pelvic abscess, three with urinary tract infection, one with voiding difﬁculty,
and one with bowel perforation. The overall survival rates were 94% in 5 years and 92.7% in 20 years. No
port-site metastasis was recorded in this study.
Conclusions: Patients with endometrial carcinoma treated by LSS had compatible or even better long-
term survival outcomes and less complication in comparison with the published data, in addition to
the beneﬁts of its minimally invasive characteristics. LSS should be the treatment of choice for endo-
metrial cancer.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Endometrial cancer is the most common gynecologic cancer of
the female genital tract in developed and developing countries, and
it occurs in postmenopausal women, with a peak incidence be-
tween 55 and 60 years of age. The incidence of endometrial cancer
increases in patients with diabetes mellitus or hypertension andnd Gynecology, Chang Gung
wei-Shan, Tao-Yuan 33305,
en).
his work.
bstetrics & Gynecology. Published bnotably in recent decades in Taiwan, probably because of lifestyle
changes among its citizens.
Most patients with endometrial cancer are diagnosed at an early
stage and treated surgically with good outcomes [1]. Complete
surgical staging for endometrial cancer includes peritoneal
cytology, exploration of the peritoneal cavity, extrafascial total
hysterectomy, bilateral salpingo-oophorectomy, and systematic
pelvic and para-aortic lymphadenectomy [2]. The idea of laparo-
scopic lymphadenectomy ﬁrst originated in combination with
Schauta's vaginal hysterectomy by Dargent [3,4]; however, Querleu
et al [5] ﬁrst reported laparoscopic pelvic lymphadenectomy in the
staging of early carcinoma of the cervix, and Childers et al [6] were
the ﬁrst to report the laparoscopic para-aortic lymph node
dissection. Childers et al [7] were also the ﬁrst to report the lapa-
roscopic treatment of endometrial cancer.y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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efﬁcacy and safety of laparoscopic oncologic surgery with at least
equivalent outcomes, including disease-free survival and overall
survival rates [8,9]. However, the results of long-term follow-up are
still few. We have been performing laparoscopic staging surgery
(LSS) for patients with endometrial cancer since 1993, and pub-
lished a preliminary report of 105 patients with good results in
2012 [10]. In this study, we extended our follow-up to 288 patients
for a period of >20 years, with the aim of evaluating the long-term
outcomes.Table 1
Patient characteristics (n ¼ 287).
Mean ± SD
Age (y) 53 ± 10.4
BMI (kg/m2) 27.3 ± 6.7Materials and methods
Between June 1995 and June 2014, we investigated 287
consecutive patients with endometrial cancer who underwent LSS
at Chang Gung Memorial Hospital, Tao-Yuan, Taiwan. Preopera-
tively, these patients were all histologically proven to have endo-
metrial cancer and assumed to be in the early stage based on
clinical assessment.
As reported previously, two experienced surgeons (C.L.L. and
K.G.H.) performed most of the surgeries, including procedures of
peritoneal lavage, hysterectomy with bilateral salpingo-
oophorectomy, pelvic and para-aortic lymphadenectomy, as well
as omentectomy for patients of serous papillary carcinoma and
clear cell carcinoma. The operation was performed with ﬁve tro-
cars, including two 12-mm and three 5-mm trocars, using a 10-mm
laparoscope via a skin incision at the midpoint of the umbilicus and
xiphoid process (LeeeHuang point), and all other ancillary ports
laterally, as described previously [11e13]. Laparoscopic hysterec-
tomy (LH) was performed via a laparoscopically assisted vaginal
approach or a total laparoscopic approach and the uterus was
removed vaginally without breaking into the endometrial cavity.
Since the revised International Federation of Gynecology and Ob-
stetrics (FIGO) staging criteria of 2009 [14], the current policy at our
institution is to perform pelvic and para-aortic lymphadenectomy
in all patients with endometrial cancer.
Patients with FIGO Stage IB Grades 2e3 and FIGO Stage IC
Grades 1e2 were clinically observed or received whole-pelvic ra-
diation and vaginal brachytherapy or chemotherapy, according to
the adverse risk factors. Furthermore, those with FIGO Stages IIA
and IIB received whole-pelvic radiation and/or vaginal brachy-
therapy. Patients with advanced stages of endometrial cancer
received adjuvant therapy with radiotherapy, chemotherapy, or
concurrent chemoradiotherapy.Cancer history (n)
Breast cancer 6
Colon cancer 5
Nasopharyngeal carcinoma 1
Molar pregnancy 1
Liver cancer 1
Hysteroscopic examination (n ¼ 126), n (%)
Positive cytology after hysteroscopy, 1 (0.79)
FIGO (2008) stage, n (%) No (%)
IA 210 (73.1)
IB 28 (9.7)
II 9 (3.1)
IIIA 9 (3.1)
IIIB 4 (1.3)
IIIC1 22 (7.6)
IIIC2 4 (1.4)
IV 1 (0.3)
Grading, n (%)
G1 161 (56.3)
G2 71 (24.7)
G3 47 (16.2)
Unknown 8 (2.8)
BMI ¼ body mass index; FIGO ¼ International Federation of Gynecology and Ob-
stetrics; SD ¼ standard deviation.Data collection and statistical analysis
Perioperative data including the operation time, number of
retrieved lymph nodes, intraoperative blood loss, length of hospi-
talization stay, and the occurrence of intra- and postoperative
complications including blood transfusion, and febrile status were
recorded, and also the pathological data including the histological
type, presence of lymphovascular space invasion, cytological ﬁnd-
ings, and the number of lymph nodes in the pelvic and para-aortic
areas. At the end of the study, the patterns of recurrence, disease-
free survival, and overall survival were analyzed.
All the data were analyzed using SPSS for Windows release
19.0.0/2010 (IBM-SPSS Inc., Chicago, IL, USA). Continuous variables
such as age and body mass index (BMI) values are presented as
mean ± standard deviation, whereas parity is presented as median
value and range. The cumulative event rates (recurrence and death)
were calculated using the KaplaneMeier method, with the time to
the ﬁrst event as the variable.Results
The characteristics of the study population are shown in Table 1.
The mean age (± standard deviation) of the patients was 53 ± 10.4
years. The mean BMI was 27.3 ± 6.7 kg/m2. Fourteen patients had a
history of other cancers: six with breast cancer, ﬁve with colon
cancer, one with nasopharyngeal carcinoma, one with a molar
pregnancy, and one with liver cancer. Of 287 patients, 126 (43.7%)
underwent hysteroscopic examination. Of these, one (0.79%) was
positive for peritoneal cytology. More than 80% of the patients had
FIGO Stage 1 cancer. As for the ﬁnal pathological ﬁndings, there
were 161 patients (56.3%) with Grade 1, 71 (24.7%) with Grade 2,
and 47 (16.2%) with Grade 3 cancer.
The intra- and postoperative characteristics are shown in
Table 2. The mean operation time was 207 ± 63.5 minutes, and the
mean blood loss was 183 ± 166.7 mL. The type of hysterectomy was
generally simple hysterectomy (84.7%), whereas some had modi-
ﬁed radical hysterectomy (10.1%) for the suspicion of cervical
involvement preoperatively. However, 15 (5.2%) patients under-
went LH and bilateral salpingo-oophorectomy only and did not
undergo other staging surgery procedures because of the very early
stage or superﬁcial involvement of the disease and the well-
differentiated characteristics (Table 2), and among young patients
oophorectomy could also be spared. None of the patients received
an autologous blood transfusion or required conversion to lapa-
rotomy. The mean numbers of pelvic lymph nodes and para-aortic
nodes removed were 18 ± 4.8 and 8 ± 5, respectively. Para-aortic
lymph node dissection was performed in 76 patients (26.4%) who
had known risk factors. The mean hospital length of stay was
6 ± 4.4 days. In total, 71 patients (24.7%) received adjuvant therapy
according to their ﬁnal surgical stage and adverse risk factors.
Nineteen patients (6.6%) underwent adjuvant chemotherapy, 12
(4.1%) radiotherapy, and 40 (13.9%) concurrent chemoradiotherapy.
The surgery-related complications are shown in Table 3. The
perioperative complications included two bladder injuries and one
bowel injury, and the postoperative complications within 30 days
included one pelvic abscess, three urinary tract infections, one
bowel perforation, and one difﬁculty voiding.
Table 2
Intraoperative characteristics (n ¼ 287).
Mean ± SD or n (%)
Duration of surgery (min) 207 ± 63.5
Estimated blood loss (mL) 183 ± 166.7
Surgical methods
Simple LH þ staging procedures 243 (84.7)
Modiﬁed radical LH þ staging procedures 29 (10.1)
Simple LAVH þ BS(O) only 15 (5.2)
Number of lymph nodes removed (n ¼ 272)
Pelvic lymph nodes 18 ± 4.8
Para-aortic lymph nodes 8 ± 5
Hospital stay (d) 6 ± 4.4
Final pathology, n
Endometrioid adenocarcinoma 271 (94.4)
Adenosquamous carcinoma 2 (0.7)
Serous carcinoma 2 (0.7)
Clear cell adenocarcinoma 8 (2.8)
Carcinosarcoma 4 (1.4)
Conversion to laparotomy, n 0
Adjuvant treatment
Chemotherapy 19 (6.6)
Radiation therapy 12 (4.1)
Chemotherapy and radiation therapy 40 (13.9)
BS(O) ¼ bilateral salpingectomy, with or without oophorectomy; LAVH ¼ laparo-
scopic assisted vaginal hysterectomy; LH ¼ laparoscopic hysterectomy;
SD ¼ standard deviation.
Table 3
Postoperative outcomes.
No.
Intraoperative complication
Bladder injury 2
Bowel injury 1
Postoperative complication (<30 d)
Pelvic abscess/hematoma 1
Urinary tract infection 3
Bowel perforation 1
Voiding dysfunction 1
Postoperative (>30 d, <180 d)
Wound infection 1
Deep vein thrombosis 1
Ileus 2
Urinary tract infection 1
Voiding dysfunction 1
Follow-up, mo; median (range) 46 (1e216)
Recurrence (n) 22
Follow-up (n) 241
Lost to follow-up (n) 24
Recurrence, mo; median (range) 12.1 (2.9e100)
Death (n)
Death from endometrial cancer 12
Death from other disease 12
Death, mo; median (range) 25.5 (2e180)
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tients experienced recurrence after a median follow-up duration of
46 months (Table 3). The total recurrence rate was 7.6%. Recurrent
disease was treated with radiotherapy or a combination of radio-
therapy and chemotherapy. No port-site metastasis occurred in this
study.
Table 4 provides an overview of the characteristics of 12 patients
who died of disease, in which seven patients were in advanced
stage and another ﬁve patients were in Stage 1. Stage 1A cases had
poorly differentiated histology with endometrioid adenocarci-
noma, and mixed endometrioid and clear cell adenocarcinoma,
whereas Stage 1B cases had deeply myometrial invasion. All
recurrent patients had high-risk tumors.
The disease-free survival rate was 89.3%. Of 287 patients, 24
(8.3%) died,12 of whom (12/287, 4.1%) died from other diseases. The5-year overall survival was 94%, and the 10-,15- and 20-year overall
survival rates were each 92.7% (Figure 1).Discussion
The present study evaluated 288 patients with endometrial
cancer undergoing LSS and with a follow-up period of 20 years,
whichdto our knowledgedis the largest study performed in a
single institution. Our results of 94% in the 5-year overall survival
rates and no laparotomy conversion needed in any patient are
apparently better than those of the previous landmark study of
LAP2 delivered by the Gynecologic Oncology Group and published
in 2009.
There has been an increasing trend to perform the surgical
treatment laparoscopically for endometrial cancer over the past 20
years [1,15,16]. We reviewed the literature for studies that enrolled
more than 100 endometrial carcinoma patients who underwent
long-term follow-up after laparoscopic surgery (Table 5)
[15,17e21]. Most of these studies compared the overall outcomes of
total LH or laparoscopically assisted vaginal hysterectomy with
those of abdominal hysterectomy for early-stage endometrial car-
cinoma. The largest study performed was the Gynecologic
Oncology Group Study LAP2 in 2009 [22], which compared lapa-
roscopy in 1682 patients and laparotomy in 920 patients. The au-
thors concluded that, with the incidence of 10% for intraoperative
complications, and 14% for the postoperatively moderate to severe
complications in the laparoscopic group, LSS for endometrial can-
cer is feasible and safe, despite a high rate of conversion to lapa-
rotomy (25.8%) [22]. Furthermore, in 2012 they reported a 5-year
overall survival rate of 89.8% in the study group [15].
The current study found a 92.7% 20-year overall survival rate. As
shown in Table 5, Malzoni et al [23] performed a prospective ran-
domized study that enrolled 81 patients who underwent total LH
with lymphadenectomy for early-stage endometrial cancer. After a
median follow-up duration of 38.5 months, the disease-free and
overall survival rates were 91.4% and 91.1%, respectively. Kalo-
giannidis et al [24] conducted a prospective, nonrandomized cohort
study of consecutive patients with clinical Stage I endometrial
adenocarcinoma. Of 169 patients, 69 underwent laparoscopic
vaginal hysterectomy with lymphadenectomy. At the median
follow-up of 51 months, the recurrence rate was 8.7%, and the
actuarial overall survival and disease-free survival rates were 93%
and 91%, respectively. Zullo et al [25] reported a prospective long-
term extension study for a randomized controlled study that
included 84 patients with clinical Stage I endometrial carcinoma. Of
those 84 patients, 40 were included in the laparoscopy group, with
a follow-up period of 78 months, and 38 comprised the laparotomy
group, with a 79-month follow-up period [25]. Seven of 40 (17.5%)
and six of 38 (15.8%) patients died in the laparoscopy and lapa-
rotomy groups, respectively, of whom six (15%) and ﬁve (13.2%)
respective patients died of the disease. Among these studies, our
study is the largest series in the literature, and it also indicated the
feasibility and safety of LSS for endometrial cancer.
In the present study, the complication rate was extremely low
compared with those reported in other studies, as shown in Table 5.
Since 2008, an additional intraoperative complication experienced
was bladder injury, seen in one case. As for the complication rate,
surgeons who have performed more than 30 laparoscopic hyster-
ectomies were associated with a signiﬁcantly lower rate of bladder,
ureteral, and bowel complications [26], and more than one-third of
the ureteral injuries that did occur were caused by surgeons who
had performed fewer than 30 laparoscopic hysterectomies [27].
These reports indicate that the surgeon’s experience with laparo-
scopic surgery has an impact on the surgical outcome.
Table 4
Patients who died of endometrial cancers.
Age (y) Pathology Stage pTNM Adjuvant
treatment
Recurrent Disease-free
interval (mo)
Overall
survival (mo)
1 63 Endometrioid
adenocarcinoma, Grade 3
IIIC1 pT1bN1M0 EP 6 cycles Peritoneal
carcinomatosis
19 23
2 54 Endometrioid
adenocarcinoma, Grade 3
IVB pT1bN0M1 EP 6 cycles, RT Liver 18 21
3 53 Serous adenocarcinoma IIIC2 pT3aN1M0 EP 4 cycles Adrenal gland,
vaginal stump
6 8
4 55 Endometrioid
adenocarcinoma, Grade 3
IIIC1 pT1bN1M0 CCRT Sigmoid colon 24 25
5 80 Endometrioid
adenocarcinoma, Grade 3
IB pT1bN0M0 RT Peritoneal
carcinomatosis
12 13
6 76 Endometrioid
adenocarcinoma, Grade 3
IIIA pT3aN0M0 RT Lung, Axilla 3 4
7 55 Endometrioid
adenocarcinoma, Grade 1
IB pT1bN0M0 CCRT Vaginal stump 11 50
8 77 Endometrioid
adenocarcinoma, Grade 3
Clear cell carcinoma
IA pT1aN0M0 d Pelvic lymph nodes 12 31
9 63 Endometrioid
adenocarcinoma, Grade 2
IIIA pT3aN0M0 n/a n/a n/a 50
10 38 Endometrioid
adenocarcinoma, Grade 3
IA pT1aN0M0 d Kidney 13 29
11 53 Endometrioid
adenocarcinoma, Grade 1
IIIA pT3aN0M0 d Lung, brain, liver 11 22
12 63 Endometrioid
adenocarcinoma, Grade 1
IB pT1bN0M0 CCRT Peritoneal
carcinomatosis
3 4
CCRT ¼ concurrent chemoradiation therapy; EP ¼ etoposide and cisplatin chemotherapy; pTNM ¼ pathological tumor-node-metastasis staging; RT ¼ radiation therapy.
Figure 1. KaplaneMeier plots showing percentage of (A) 5-year, (B) 10-year, (C) 15-year, and (D) 20-year overall survival. The 5-year overall survival rate was 94%, and 10-, 15-, and
20-year overall survival rates were each 92.7%.
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Table 5
Literature reviews for the surgical outcomes for the LSS for endometrial cancer.
Study design
Eltabbakh 2002 [18] Cho 2007 [19] Tinelli 2011 [21] Palomba 2012 [20] Walker 2012 [15] Lu 2013 [17] Current study
Retrospective Retrospective Retrospective,
multicenter study
Retrospective,
multicenter study
Prospective
GOG study LAP2
Prospective Retrospective
Study pt no. (n) 100 165 123 403 1696 151 287
Open pt no. (n) 86 144 103 609 920 121
Age (y),
mean ± SD (range)
62 ± 12.9
(16e89)
50
(26e77)
62 ± 13 53 ± 12 62.8
(23.9e92.8)
56.6 (27e82) 53 ± 10.4
BMI (kg/m2),
mean ± SD (range)
28.8 ± 7.1
(17.8e49.6)
25.6
(16.9e42.4)
27 ± 7.3 27 ± 4.5 28.4
(14.9e65.3)
26.4 27.3 ± 6.7
Surgical stage (%)
Ia 42 32.7 30.8 12.9 69.6 39 73.1
Ib 31 55.8 29.2 61.5 12.6 36.4 9.7
Ic 10 6.1 18.6 17.4 d 15.2 d
IIa 3 2.4 4.8 3 4 6.6 3.1
IIb 5 3 2.4 1.2 d d
III 7 0 12.7 3.7 11.5 2.6 13.5
IV 2 0 0 0.2 2.4 0 0.3
Grade (%)
1 57 57 34.9 47.4 d 62.9 56.3
2 26 32.7 46 35.2 d 26.4 24.7
3 17 10.3 18.6 17.4 d 10.5 16.2
Lymph node removed
Pelvic, n (mean) 11 ± 5.1 26.2 (1e70) 22.9 ± 6.3 16 ± 6 17 (12e23) 18 ± 4.8
Para-aorta, n (mean) 2.5 ± 1.9 4.9 (1e20) 9.8 ± 3.1 5 ± 3 7 (4e11) 8 ± 5
Total, LN (mean) 27.1 (1e70) 25 (10e41)
Conversion to open (%) 6 5.30 0 13.2 25.8 d 0
Lymphadenectomy PLA 86%
PALA 24%
PLA 89.7%
PALA 17.6%
PLA 100%
PALA 21.1%
PLA 47.6%
PALA 10.2%
PLAþPALA 95.8% PLA 100%,
PALA 15%
(sampling 80%)
Complication (%) 11% 9.1 7.3
(intraoperative),
33.3
(postoperative)
10
(intraoperative)
12 1.0
(intraoperative)
4.1 (postoperative)
Disease-free survival (%) 90 (5 y) 95.5 (5 y) 91.9 73.2 89.3
Overall survival (%) 92 (5 y) 98 (5 y) 94.4 77.9 89.8 (5 y) 94 94 (5 y)
Median follow-up, mo 27 28 49.5 49 59 68 46
BMI ¼ body mass index; LSS ¼ laparoscopic staging surgery; PALA ¼ para-aortic lymphadenectomy; PLA ¼ pelvic lymphadenectomy; pt ¼ patient.
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Risk factors for conversion to laparotomy included the patient’s BMI
and age in the Laparoscopic Approach to Cancer of the Endome-
trium (LACE) trial [28]. In the LAP2 trial, the failure to complete
laparoscopy was greater with increasing age and BMI and with
metastatic disease [22]. One of the reasons for our zero conversion
could be a tendency toward a younger age and lower BMI among
patients in our study compared with those in other reports, as
shown in Table 5. Many studies have also supported such results
[29,30]. We noted that a learning curve really existed, wherein
operative time, hospital stay duration, and conversion rate to lap-
arotomy associated with LSS would decrease with increasing
operation experience [31], and the number of pelvic lymph nodes
removed would also increase with increased surgeon experience
[32], as we have experienced a high degree of familiarization for
over two decades in practicing cancer laparoscopies, including
laparoscopic radical trachelectomy [33], and natural oriﬁce adnexal
surgery and endometrial cancer [4,34]. Another reason for our zero
conversion could be the incorporation of the LeeeHuang point,
which enables a wider surgical ﬁeld and safe performance of
lymphadenectomy.
We routinely performed lymphadenectomy for patients with
early-stage endometrial cancer, and this could be one of the
possible reasons for a better survival prognosis in the present
study. Todo et al [35] reported that among patients at an inter-
mediate or high risk of recurrence, overall survival was signiﬁ-
cantly longer in the pelvic and para-aortic lymphadenectomy
group than in the pelvic lymphadenectomy group. Cragun et al[36] found that after removing patients reported to have pelvic or
aortic nodal metastasis from their analysis, more extensive lym-
phadenectomy was associated with improved survival. Although
it is controversial to perform lymphadenectomy in all endometrial
cancer patients, this procedure may have a therapeutic beneﬁt
selectively in patients with an intermediate or high-risk of
recurrence [37]. Accordingly, the number of lymph node removal
could not only be an issue of precise staging for pathologic diag-
nosis, but also regarding the radicality of cancer surgery. There-
fore, we suggest that lymphadenectomy be routinely performed
in LSS.
In the present study, 126 patients who underwent hysteroscopic
examination preoperatively resulted in only one (0.79%) patient
positive for peritoneal cytology detected intraoperatively, indi-
cating that preoperative hysteroscopy does not increase the risk for
spread of cancer cells and is not correlated with poor prognosis
[38,39]. Hysteroscopy is a gooddif not the bestddiagnostic tool in
some difﬁcult cases to differentiate whether the tumor originates in
the endometrium or in the endocervix.
Fourteen patients in the current study had ﬁve other asso-
ciated malignancies, one of which was colon cancer, which is
associated with the hereditary cancer, Lynch syndrome. Lynch
syndrome, known as hereditary nonpolyposis colorectal cancer,
is the most common form of hereditary colorectal cancer and
hereditary endometrial cancer. The frequency of Lynch syn-
drome was reported to be approximately 1e2% in colorectal
cancer patients [40,41], and we had ﬁve patients (1.7%) with
colon cancer in our study. We need to pay more attention to
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histories.
This study had the limitation of being a single-arm case series
and in its retrospective nature, which pose potential threats to in-
ternal validity caused by confounding or bias. However, the patients
usually come to Dr Lee and Huang's clinics seeking for laparoscopic
operation, and none of them had given consent for laparotomy.
Thus, the study can only be sequential, and it is difﬁcult to have a
counterpart of laparotomy to compare with.
In conclusion, few surgical complications and good survival
outcomes were noted in the current series for LSS in treating pa-
tients with endometrial cancer. Hysteroscopic diagnosis and exci-
sional biopsies for endometrial carcinoma did not seem to
predispose the risk of intraperitoneal dispread or hamper the
prognosis of treatment. As no laparotomy conversion happened
herein, its incidence should be rare in the hands of experienced
endoscopists. In addition to the beneﬁts of its minimally invasive
characteristics, patients treated by LSS in the current series had
overall survival rates 94% in 5 years and 92.7% in 20 years,
respectively, which is compatible or even better than the published
data in the literature. Therefore, traditional laparotomy in staging
surgery should be replaced with LSS in a move to push the progress
of minimally invasive therapy into the next era.
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